Search results for: Pricing and Reimbursement

Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer

10 June 2024

…experts, research and innovation funders, innovators in research institutes and industry, regulators, health technology assessment expertise, policymakers and payers, and the patient voice. TPP development has two key stages: inception…

Dr. Inmaculada Hernandez

3 September 2024

Dr. Inmaculada (Inma) Hernandez is a Professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hernandez is a pharmacist and a scholar whose…

Terms and Conditions

…interest in and to the site and all of the content, software, code, data and other materials therein, and the look-and-feel, design and organisation of any aspect thereof, including any…

Personalised Medicine: Is it an Oil-Rush or Oil-Spill?

3 February 2020, 12:00am

…acquired in an interpretable manner, is useful. However, it is also disruptive and has the potential to challenge many existing institutions, regulations and pricing patterns. Some empirical examples will be…

2010 Lecture: US Health Care Reform

27 May 2010

…and the implications for both public and private programs Changes in the nature and extent of the demand for services that may affect, for example, preventive care, primary care, and…

Exploring Local NHS Decisions about Investment

4 February 2011

…Health Economics at the University of York. For the coming few months, he will be based at OHE working with Professors Nancy Devlin (OHE’s Director of Research) and with David…

Two Economists Join OHE

10 March 2011

…of competition and regulation, and UK and EU competition law. Prior to the OHE, Arik was with the UK Competition Commission, where he was involved in a wide range of cases…

New: 50 Years of OHE Publications Are Available Online

2 April 2012

…Since the early days of the OHE, another key issue has been how best to define, encourage and evaluate innovation in medicine and medicines. Although perspectives and approaches have evolved,…

New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?

14 June 2012

…higher risk, and public incentives, e.g. allowing only “breakthrough” drugs to be eligible for higher pricing. In comparing R&D performance of companies based in the US and Europe, Prof Riccaboni…